CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

This study is testing a specific chemotherapy combination called CRP (which includes rituximab, a targeted antibody drug) for elderly patients with a particularly aggressive type of lymphoma called double-expressor diffuse large B-cell lymphoma (DLBCL) — cancer where two specific proteins (MYC and Bcl-2) are both overactive, making the cancer harder to treat. **You may be eligible if...** - You are 70 or older, OR between 60 and 69 with limited physical function (ECOG score 2–4) - You have been newly diagnosed with CD20-positive DLBCL that is also double-expressor (both MYC and Bcl-2 positive) - You have not received any prior treatment for DLBCL - You have at least one measurable tumor visible on PET-CT scan - You are expected to live at least 6 months **You may NOT be eligible if...** - You have another active cancer - You have previously received CHOP chemotherapy or the drug chidamide - You have had a recent heart attack or serious heart condition - You are pregnant or breastfeeding - You have CNS (brain or spinal cord) lymphoma Talk to your doctor to see if this trial is right for you.